The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 (ENDCOV-I)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04619680 |
|
Recruitment Status :
Recruiting
First Posted : November 6, 2020
Last Update Posted : October 12, 2022
|
Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
Boehringer Ingelheim
Information provided by (Responsible Party):
Maria L Padilla, Icahn School of Medicine at Mount Sinai
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 2024 |
| Estimated Study Completion Date : | April 2024 |